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Cathepsin B1 (SmCB1) is a digestive protease of the
parasitic blood fluke Schistosoma mansoni and a
drug target for the treatment of schistosomiasis, a
disease that afflicts over 200 million people. SmCB1
is synthesized as an inactive zymogen in which the
N-terminal propeptide blocks the active site. We
investigated the activation of the zymogen by which
the propeptide is proteolytically removed and its
regulation by sulfated polysaccharides (SPs). We
determined crystal structures of three molecular
forms of SmCB1 along the activation pathway: the
zymogen, an activation intermediate with a partially
cleaved propeptide, and the mature enzyme. We
demonstrate that SPs are essential for the autoca-
talytic activation of SmCB1, as they interact with a
specific heparin-binding domain in the propeptide.
An alternative activation route is mediated by an
S. mansoni asparaginyl endopeptidase (legumain)
which is downregulated by SPs, indicating that SPs
act as a molecular switch between both activation
mechanisms.
INTRODUCTION
Schistosomiasis (bilharzia) is a chronic infectious disease
caused by trematode blood flukes of the genus Schistosoma.
The disease infects over 200 million people and is second only
to malaria as a global parasitic health problem (Colley et al.,
2014). Schistosoma mansoni is the most widespread of the
human-infecting schistosomes. Treatment and control of schis-
tosomiasis now relies on just one drug, and because of the
growing concern over resistance, there is pressure to identify
new chemotherapeutic strategies (Caffrey, 2007; Caffrey and
Secor, 2011; The´tiot-Laurent et al., 2013).1786 Structure 22, 1786–1798, December 2, 2014 ª2014 Elsevier LtdAdult schistosomes live in the cardiovascular system, and
host blood proteins are a primary source of nutrients. In the
schistosome gut, a network of proteases performs the digestion
of host proteins (Brindley et al., 1997; Caffrey et al., 2004; Del-
croix et al., 2006) and represents a potential intervention target.
The present research focuses on S. mansoni cathepsin B1
(SmCB1), which is a central digestive protease because of its
high abundance and complex proteolytic activity that comprises
both endopeptidase and exopeptidase (peptidyl-dipeptidase)
modes of action (Caffrey and Ruppel, 1997; Sajid et al., 2003; Jı´l-
kova´ et al., 2011). SmCB1 has been validated in a murine model
of schistosome infection as a molecular target for therapy (Ab-
dulla et al., 2007). Recently, we determined the crystal structure
of SmCB1 in complex with peptidomimetic inhibitors to describe
the binding mode and correlated their inhibition of SmCB1 with
antischistosomal potency (Jı´lkova´ et al., 2011).
Members of the clan CA, family C1 (papain-like) cysteine
peptidases, including cathepsins B, are synthesized as inactive
zymogens (procathepsins), in which the propeptide acts as an in-
tramolecular inhibitor by blocking the active site (Cygler et al.,
1996; Podobnik et al., 1997; Redecke et al., 2013). Activation
to the mature, catalytically active form occurs upon proteolytic
removal of theN-terminal propeptide (also termed the ‘‘activation
peptide’’), and this can be autocatalytic or involve another trans-
activating protease (for review, see, e.g., Turk et al., 2012). For re-
combinant SmCB1, the zymogen does not autoprocess but was
trans-activated by S. mansoni asparaginyl endopeptidase/legu-
main (SmAE; Sajid et al., 2003), a clan CD cysteine peptidase
(Dalton and Brindley, 1996; Caffrey et al., 2000). However, a later
in vivo study demonstrated that SmAE was not absolutely
required for SmCB1 activation (Krautz-Peterson and Skelly,
2008), indicating that a different mechanism may also contribute
to the maturation of SmCB1. We propose that this alternative
mechanism is an autoactivation eventmediated by sulfated poly-
saccharides (SPs), such as glycosaminoglycans (GAGs).
SPs have a strong negative charge and are widely distributed
in tissues participating in the regulation of a number of protein
functions and interactions (for example reviews, see Raman
et al., 2005; Gandhi and Mancera, 2008). SPs are also reportedAll rights reserved
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example, they induce the collagenolytic activity of cathepsin K
(Li et al., 2002; Cherney et al., 2011), stabilize cathepsin B at
neutral pH (Almeida et al., 2001), and facilitate the autoactivation
of cathepsins B, L, and S (Vasiljeva et al., 2005; Caglic et al.,
2007; Fairhead et al., 2008).
Here, we show that SPs do more than just modulate the activ-
ity of cysteine cathepsins but are critically required for the au-
toactivation of SmCB1.Moreover, they act as amolecular switch
in the SmCB1 activation pathway by alternating between au-
toactivation and trans-activation. The bimodal activation system
described here for SmCB1might also be relevant to other diges-
tive cathepsins B of parasitic metazoa, including other trema-
todes and hookworms (Beckham et al., 2006; Ranjit et al.,
2008; Horn et al., 2011). We provide insights into the mechanism
of activation of cysteine cathepsins by using a complete set of
structures along the activation pathway, including the zymogen
and mature forms, and a unique processing intermediate.
RESULTS
Determination of Crystal Structures
A recombinant zymogen of SmCB1 was produced in the Pichia
pastoris expression system (Sajid et al., 2003; Horn et al.,
2011). The inactive intermediate (iCBinact) was obtained from
the zymogen by autocatalytic processing, which removed 38
residues from the propeptide generating N-terminal Leu39 (the
SmCB1 zymogen numbering is used throughout the paper).
The enzymatically active mature form of SmCB1 was prepared
from the zymogen by trans-activation (Sajid et al., 2003; Horn
et al., 2011), which removed the full-length, 69-residue-long pro-
peptide to reveal an N-terminal Val70. For crystallographic
studies of the zymogen, an inactivated mutant was constructed
with mutated active-site cysteine (Cys100Ser) to prevent its
autoprocessing.
The crystal structures of the zymogen, the intermediate
iCBinact, and the mature enzyme were determined by molecular
replacement using the structure of the mature SmCB1 com-
plexed with the inhibitor CA-074 (Jı´lkova´ et al., 2011). The
zymogen crystallized in the triclinic space groupP1with fourmol-
ecules per asymmetric unit. All four molecules are very similar;
the root-mean-square deviation (rmsd) for the superposition of
the four protein molecule backbones onto one another ranges
from 0.2 to 0.3 A˚. The structure was refined using data to a reso-
lution of 1.95 A˚. N-terminal residues 1 to 8, 1 to 7, 1 to 5, and 1 to 5
and residues 179 to 189, 181 to 186, 179 to 190, and 180 to 189
within the occluding loop could not be located in the electron
density map in molecules A, B, C, and D, respectively, and
were thus not included in the final model (these two regions are
also disordered in several zymogen structures of mammalian ca-
thepsins B; Cygler et al., 1996; Podobnik et al., 1997). For presen-
tation purposes, the missing residues were computationally
modeled for the most complete molecule B (Figure 1).
The intermediate iCBinact crystallized in the monoclinic space
groupC2with onemolecule in the asymmetric unit. The structure
was refined using data to a resolution of 1.9 A˚. The first eight
N-terminal residues in the molecule could not be located in the
electron density map and were thus not included in the final
model, which starts with Gly47.Structure 22, 1786–17The mature enzyme crystallized in the orthorhombic space
group P212121 with one molecule in the asymmetric unit. The
structure was refined using data to a high resolution of 1.3 A˚.
No electron density was found for the N-terminal residue, so
the final crystallographic model starts with Glu71.
Structural Characterization of the SmCB1 Zymogen and
Its Processing Sites
In the SmCB1 zymogen, the enzyme core adopts the classical
fold of papain-family proteases in which the molecule is divided
into L and R domains with the active-site cleft located in between
(Figure 1A). The active site contains the catalytic residues
Cys100, His270, and Asn290 and is blocked by the propeptide,
which binds along the cleft in the opposite direction compared
with substrates. This inhibitory mechanism and the overall archi-
tecture of the propeptide resemble cathepsin B-type propepti-
des (Cygler et al., 1996; Podobnik et al., 1997; Redecke et al.,
2013); however, the secondary structure of the SmCB1 propep-
tide incorporates an additional a helix, a3p (Figure S1 available
online). The interface between the propeptide and the enzyme
core contains a net of interactions (listed in Table S1), and the
propeptide is further stabilized by a network of intramolecular
contacts (Table S2).
The propeptide chain (residues 8–69) wraps around the
enzyme core, forming three topological regions (Figure 2E): (1)
a hairpin structure formed by the a1p helix (residues 13–22) fol-
lowed by an antiparallel b1p strand (residues 28–30), (2) the a2p
helix (residues 38–44) followed by the active site-binding seg-
ment, and (3) the nonconserved a3p helix (residues 52–60)
followed by the propeptide/mature N terminus junction.
The a1p-b1p hairpin segment of the propeptide interacts with
a large ‘‘propeptide-binding loop’’ (PBL; residues 247–265) of
the enzyme core (Figure 2A). The majority of the contacts are
formed by residues 27 to 31 from b1p, including hydrogen bonds
with a short antiparallel part of the PBL (Tyr254–Tyr259); Trp28 is
also a part of an aromatic cluster along with two central residues,
Tyr254 and Tyr259, of the PBL.
Propeptide residues 33 to 44 follow a crevice located between
the ‘‘occluding loop’’ (residues 178 to 192) and the PBL of
the enzyme core (Figure 2B). Residues 33 to 37 are organized
into a kink and residues 38 to 44 into the a2p helix. The interface
interactions are provided mostly by hydrogen bonds and salt
bridges of Arg35 from the kink and Asp41 and Ile44 from a2p.
No direct hydrogen bonding was found between the propeptide
and the occluding loop, but Asp41 in a2p is interconnected via
the enzyme-core residue Arg96 with Lys192 and Tyr194 of the
occluding loop (Figure 1B). The occluding loop is in ‘‘open’’
conformation, like in other cathepsin B-type zymogens (Cygler
et al., 1996; Podobnik et al., 1997; Redecke et al., 2013), with
a highly flexible tip (residues 181–186 are partially disordered
with poorly defined electron density). In this region, there are sig-
nificant local changes when comparing SmCB1 with other
cathepsin B-type zymogens, in which the propeptides are posi-
tioned closer to the occluding loop and their interactions are
maintained by a set of hydrogen bonds. The cleavage site
(Ser38-Leu39) that is processed to yield the intermediate form
iCBinact is located on the rim of the a2p helix (Figure 1C). The sur-
rounding region (His37-Asp40) forms no hydrogen bonds with
the enzyme core and is exposed to the solvent; the accessibility98, December 2, 2014 ª2014 Elsevier Ltd All rights reserved 1787
(legend on next page)
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occluding loop.
The propeptide residues 45 to 49 occupy the S20 and S3 sub-
sites of the substrate-binding cleft (Figure 2C). The S20 subsite
accommodates Gln45, which forms hydrogen bonds with Gln94
and Trp292, and is in contact with the catalytic His270. The S10
subsite is occupied by Met46 hydrogen-bonded to Gln94 and
Ser100, the latter of which was mutated from the catalytic Cys
residue. Gly47 enters the S1 subsite and interacts via hydrogen
bondswithGly144.Ala48andArg49are in theS2andS3subsites,
respectively, where they form a total of three hydrogen bonds.
The nonconserved a3p helix contains a heparin-binding motif
(based on the arginine pattern in the LRRTRRP sequence, res-
idues 55–61), which is absent in other structurally characterized
cathepsin B zymogens (Horn et al., 2011). The a helix makes
only a few contacts with the enzyme core through hydrogen
bonds formed by Arg56 and Arg60, but it is internally stabilized
by hydrogen bonds between the solvent-exposed Arg59
and Arg57 of the motif and the adjacent acidic residues of
the propeptide (Arg57-Asp54, Arg59-Glu51-Arg60) (Figures
1C and 2D). This arrangement of contacts and the position of
a3p protruding above the enzyme-core surface provide a target
for GAGs.
Downstream of a3p is the cleavage site Asn69-Val70, which is
processed to yield the mature enzyme. The processing region
(residues 64–72) has a limited number of hydrogen bonds
at the interface between the propeptide and the enzyme core
(Figure 1C); the interaction is maintained by several hydrophobic
residues oriented against the core while an array of four Asp
and Asn side chains is exposed to the solvent, thus making
this stretch easily accessible to proteolysis.
Structural Characterization of the SmCB1 Intermediate
and Mature Forms
The mature form of SmCB1 is derived from the zymogen by
proteolytic removal of the full-length propeptide (Figure 1A).
The rmsd for the superposition of the main-chain atoms of the
zymogen and the mature enzyme is 1.1 A˚, and the major differ-
ence in both protein backbones is within the occluding loop. ItsFigure 1. Structural Comparison of the Processing Forms of SmCB1 a
(A) Overall crystal structures of three processing forms of SmCB1, including the
mediate (iCBinact) with partially processed propeptide (residues 39–69), and the
cartoon representation with the propeptide in orange and the enzyme core in gree
His270 are depicted in ball-and-stick representation in yellow. The arrowheads
iCBinact andmCB (blue and red arrowheads, respectively). The secondary structur
terminus is marked by N.
(B) Rearrangement of the occluding loop associated with the propeptide process
enzyme core/propeptide are shown as sticks (themain chains or side chains are p
pCB (green; the flexible modeled part is yellow) is in the ‘‘open’’ conformation dicta
occluding loop of iCBinact (cyan) and mCB (magenta) is in the ‘‘closed’’ conform
respectively) and occluding loop residues are labeled in magenta. The yellow sti
(C) Structural details on proteolytic processing sites within the propeptide (for o
resentation with side chains as sticks (the heteroatoms are colored as in B). Depic
the internal hydrogen bonds within the propeptide (black dashed lines). The enz
represented as sticks; the surface of the residues forming hydrogen bonds with
green. Left: the cleavage site where the propeptide is processed to yield iCBin
indicated by the blue arrowhead. The flexible tip of the occluding loop is shown in t
is processed to yield mCB is surface exposed at the propeptide/enzyme core junc
a3p helix with the heparin-binding motif (containing Arg56, Arg57, Arg59, and Ar
Structure 22, 1786–17‘‘open’’ conformation in the zymogen imposed by the propeptide
is changed to the ‘‘closed’’ conformation after propeptide
removal (Figures 1A and 1B). In contrast to the zymogen, the tip
of the occluding loop in themature enzyme iswell defined in elec-
tron density (residues 178–189) because of stabilization, which is
provided by 13 hydrogen bonds (Figure 1B). The largest move-
ment (10 A˚) in the occluding loop during open-to-closed transi-
tion was found for His180. In the mature enzyme, two conserved
residues, His180 and His181, are oriented into the active site,
where they restrict access to the primed region and can interact
with the C-terminal carboxyl group of the substrate P20 residue
(Jı´lkova´ et al., 2011); the histidines form hydrogen bonds with
Asp93 and Leu252. The occluding loop is further rearranged be-
tween residues188and194 (6 A˚movement forSer191/Gly190),
and this conformation is stabilized by a net of hydrogen bonds
of Tyr194, Pro188, and Cys189 to the core residue Arg96. The
active site of the noncomplexed mature enzyme resembles that
determined in the complexes with peptidomimetic inhibitors
(Jı´lkova´ et al., 2011), but the absence of a ligand results in higher
flexibility of His270, as indicated by a double conformation of its
side chain. The catalytic Cys100 was found to be oxidized.
The intermediate iCBinact is a structural chimera with com-
bined features of the SmCB1 zymogen and the mature enzyme
(Figure 1A). It is derived from the zymogen by proteolytic removal
of the first half of the propeptide (residues 1–38); the newly
formed N-terminal segment 39 to 46 is flexible, and the electron
density only becomes defined downstream of Gly47. The resid-
ual propeptide interacts with the substrate-binding cleft by three
residues, Gly47, Ala48, and Arg49, located in S1, S2, and S3
subsites, respectively. The majority of iCBinact propeptide inter-
actions in the active site as well as of downstream propeptide
regions, including the a3p helix and the propeptide/mature
N terminus junction, are similar to the zymogen. Likewise, the
enzyme core of iCBinact is highly similar to that in the mature
enzyme, with an rmsd for the superposition of the main-chain
atoms of 0.4 A˚. Specifically, the occluding loop has an analogous
shape and position, and interdomain interactions except for
the missing hydrogen bonds between His181 and Leu252 and
between Thr182 and Lys255 (Figure 1B).long the Activation Pathway
zymogen (pCB) with full-length propeptide (residues 1–69), the inactive inter-
mature enzyme (with N-terminal residue 70). The 3D structures are shown in
n (pCB), cyan (iCBinact), andmagenta (mCB). The catalytic residues Cys100 and
mark the positions of the cleavage sites, which are processed, giving rise to
e elements in the propeptide are labeled, the occluding loop is boxed, and the N
ing. The residues forming hydrogen bonds between the occluding loop and the
resented; heteroatoms are red and blue for O and N). Left: the occluding loop of
ted by the propeptide (orange); the enzyme core residues are in gray. Right: the
ation; the enzyme core residues are in gray and light blue (iCBinact and mCB,
cks represent disulfide bridges.
rientation, see A). The propeptide in pCB is shown in the orange cartoon rep-
ted are the hydrogen bonds between the propeptide and the enzyme core, and
yme core is shown as a transparent surface with hydrogen-bonded residues
the propeptide is colored in pale cyan, the other contact residues are in lime
act is surface exposed at the a2p helix; the hydrolyzed Ser38-Leu39 bond is
he yellow cartoon representation. Right: the cleavage site where the propeptide
tion; the hydrolyzed Asn69-Val70 bond is indicated by the red arrowhead. The
g60) is located in the vicinity.
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Figure 2. The Interface between the Pro-
peptide and the Enzyme Core
(A–D) In the SmCB1 zymogen, the propeptide in-
teracts with the following regions of the enzyme
core: (A) the PBL, (B) a crevice between the PBL
and theoccluding loop, (C) the active site cleft, and
(D) the region binding the a3p helix. The propep-
tide is shown in cartoon representation in orange;
the residues forming hydrogen bonds (or having
specific structural roles) are depicted as sticks.
Top: the enzyme core is shown as a gray surface
with the residues forming the interface hydrogen
bonds inpale cyanand thecontact residues in lime
green. Bottom: the residues of the enzyme core
forming the interface hydrogen bonds are shown
in stick representation in gray. The hydrogen
bonds between the propeptide and the enzyme
core are indicated as black dashed lines.
(E) The regions presented in (A)–(D) are boxed in
the SmCB1 zymogen model. The propeptide is
shown as an orange cartoon and the enzyme core
as a gray surface; the position of the active site is
highlighted by catalytic residues in yellow.
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Zymogen
The autocatalytic activation of the SmCB1 zymogen was inves-
tigated using two different assays: SDS-PAGE visualization
of the processing forms and kinetic measurement of their
proteolytic activity. The effect of SPs on the activation process
was probed with dextran sulfate (DS) as a model GAG-like poly-
saccharide. In the absence of DS, the auto-processing of the
zymogen (37 kDa) was effective at acidic pH, at pH 5.0 and
below, and resulted in an intermediate form of 32 kDa, which
did not yield any proteolytic activity (Figures 3A and 3B). In the
presence of DS, the zymogen was converted in the same pH
range into mature SmCB1 (28 kDa) via an intermediate species
(30–31 kDa) (Figure 3A). This was associated with the genera-
tion of proteolytic activity that was stable at pH 5.0 (and declined
at lower pH because of autodegradation, as demonstrated by
SDS-PAGE). At pH 5.5 with DS, the inactive 32 kDa intermediate
was produced (Figures 3A and 3B).
The activity-based probe Green-DCG-04 (Greenbaum et al.,
2002) was applied to label the active site of the variously pro-
cessed forms of SmCB1, which could then be visualized by
SDS-PAGE (Figure 3C). The mature enzyme was intensively1790 Structure 22, 1786–1798, December 2, 2014 ª2014 Elsevier Ltd All rights reservedlabeled, whereas the zymogen did not
show a significant signal. Regarding the
intermediates, the 30 to 31 kDa form,
but not the 32 kDa form, interacted with
the probe, indicating that only the former
contains an accessible active site.
The cleavage sites in the SmCB1 pro-
peptide during the autocatalytic process-
ing were identified using N-terminal pro-
tein sequencing; their localization is
presented in the 3D model in Figure 4.
This cleavage map helps explain the dif-
ference in the activity status of both inter-
mediates. The inactive 32 kDa intermedi-ate corresponds to the crystallographically characterized iCBinact
(Figure1) and isderivedby thecleavageof theSer38-Leu39bond;
this form keeps the propeptide region intact with Met46 and
Gly47 blocking the S10 and S1 subsites. In contrast, the active
30 to 31 kDa intermediate (iCBact) has a heterogeneous N termi-
nus produced by cleavages of the Met46-Gly47 bond and in its
close vicinity, thus opening the catalytic site for substrate entry.
To analyze the cleavage pattern in the propeptide in detail,
synthetic peptides derived from the propeptide structure were
used as a substrate for the hydrolysis catalyzed by mature
SmCB1 (Figures 4 and S2). Interestingly, we found a striking dif-
ference in the distribution of the cleavage sites identified in the
peptides digested in the presence and absence of DS. Whereas
both cleavage patterns in the N-terminal half of the propeptide
(upstream of Met46-Gly47) are rather similar, the C-terminal
half (downstream of Met46-Gly47) was fragmented only in the
presence of DS, including thematuration Asn69-Val70 bond. Ex-
periments withmodified peptides described in the Supplemental
Information (Figure S2) suggested that DS interacts with the
heparin-binding motif and increases accessibility and suscepti-
bility to proteolysis in the same parts of the propeptide that are
cleaved during autoactivation.
Figure 3. The SmCB1 Zymogen Is Autoactivated in the Presence of an SP
The SmCB1 zymogen (75 nM) was incubated in the presence or absence of DS (10 mg/ml) at various pH values, and the reactionmixture was analyzed at different
time points.
(A) The autoprocessed forms were resolved by SDS-PAGE and visualized by protein staining. The position is indicated for the zymogen (pCB), mature enzyme
(mCB), and intermediates (iCB, including an inactive 32 kDa form, iCBinact, and an active 30–31 kDa form, iCBact).
(B) Proteolytic activities generated during the autoprocessing were determined in a kinetic assay with the fluorogenic substrate Z-Phe-Arg-AMC at pH 6.0. Mean
values ± SE are expressed in relative fluorescence units (RFU/s).
(C) Imaging of the individual processing forms of SmCB1was performedwith the fluorescent active-site probe Green-DCG-04. The proteins were treated with the
probe, resolved by SDS-PAGE, and visualized with a fluorescence imager (DCG04) and by protein staining (CBBlue). The processed forms were as follows:
purified zymogen (pCB) andmature enzyme (mCB); intermediates obtained by the autoprocessing of pCB at pH 5.0 in the presence of DS (iCBact) and at pH 4.0 in
the absence of DS (iCBinact).
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tivation of the inactive SmCB1 zymogen to the mature active
enzyme. In its absence, the autoactivation is not productive
and leads to an incompletely processed propeptide that ob-
structs the catalytic site. Furthermore, the molecularity of the
autocatalytic processing of SmCB1 was examined by several
approaches, including the effect of the zymogen concentration
and processing of the active-site mutated zymogen by the
mature enzyme as presented in the Supplemental Information
(Figure S4). This revealed that the SP-independent initiation
of the zymogen autoprocessing involves a critical rate-limiting
intramolecular step leading to the intermediate form, whereas
the SP-dependent full autoactivation via the intermediate to
mature enzyme is an intermolecular process.
The Heparin-Binding Motif in the Propeptide Is
Necessary for the Correct Maturation of SmCB1
Mediated by SPs
The SmCB1 propeptide contains a consensus sequence for the
binding of heparin (and related SPs); this XBBXBBXmotif (where
B is a basic amino acid and X is a hydropathic amino acid) is
located at residues 55 to 61 (see Figures 1 and 4). To study its
role in the autoactivation of the SmCB1 zymogen, we con-Structure 22, 1786–17structed SmCB1 mutants in which the function of the motif
was abolished by substituting two Arg residues (R57/R59) with
Ala or Asn. Both heparin-binding motif mutants were produced
as correctly folded zymogens that could be trans-activated by
asparaginyl endopeptidase into mature enzymes with activities
comparable with the control mature enzyme (see the Supple-
mental Experimental Procedures).
Figure 5 shows the acidic autoprocessing of the mutant zymo-
gens. In the absence of DS, they were converted into the inter-
mediate form cleaved at the same position as the control
zymogen (Figure S3), although with a higher efficiency. In the
presence of DS, there is a striking difference in the processing
patterns. The motif mutants were processed into a set of inter-
mediate forms under the conditions in which the control
zymogen was converted into the mature enzyme via the active
intermediate (Figures 5 and S3). The N-terminal sequencing of
the intermediates derived from the mutants revealed that some
of them are processed at and downstream of the region in the
propeptide that blocks the catalytic site (Figure S3). This is in
line with the enzymatic activity generated in the processing mix-
tures (data not shown).
In conclusion, an intact heparin-binding motif in the SmCB1
propeptide and its interaction with an SP are necessary for the98, December 2, 2014 ª2014 Elsevier Ltd All rights reserved 1791
Figure 4. Autoprocessing Cleavage Sites in the Propeptide of SmCB1
(A) The amino acid sequence of the SmCB1 propeptide is shown with secondary structure elements derived from the crystallographic model (H, a helix; E, b
strand). The heparin-binding motif is highlighted in green, and the residues that interact with the S1 and S10 subsites of the active site are in red. The triangles
above the sequence indicate cleavage sites generated during the acidic autoprocessing of the SmCB1 zymogen and determined by the N-terminal sequencing.
Processed products were obtained in the presence (red triangles) or absence (blue triangles) of DS. The solid triangles mark the major final cleavage sites,
whereas the small open triangles denote the minor cleavage sites. The position of N termini is indicated for the zymogen (pCB), inactive (iCBinact), and active
(iCBact) intermediates and mature enzyme (mCB). The dots below the sequence indicate the cleavage sites, which were identified in synthetic propeptide
segments digested by mature SmCB1 in the presence (red dots) or absence (blue dots) of DS (Figure S2).
(B) The 3D structure of the SmCB1 zymogen shows the location of the autoprocessing sites represented by the triangles in (A). The propeptide is depicted as a
black cartoon with the heparin-binding motif in green, and the mature enzyme core is shown as a gray surface with the catalytic residues in yellow. In the
propeptide, the DS-dependent (red) and DS-independent (blue) cleavage sites are highlighted andmarked (as C-terminal residues of cleaved bonds). The arrows
indicate the processing sites generating the inactive intermediate iCBinact (blue) andmature enzyme (red); the side chains of the residues flanking the cleavage site
are shown.
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matured enzyme.
The Action of SPs Depends on Their Type, Size, and
Concentration
Throughout this study, we used DS as a model SP mimick-
ing natural GAGs, such as heparins and chondroitin and der-
matan sulfates. Now, we compare their effect on the SmCB1
autoprocessing.
Figure 6A shows that both DS and a similarly sized heparin
mediated the regular autoactivation of the zymogen to the
mature enzyme, although the heparin-mediated conversion
was slower. In contrast, chondroitin sulfates and dermatan sul-
fate induced the production and accumulation of the intermedi-
ate, which was, however, not further processed to the mature
enzyme. The size of SPs required for mediating the autoactiva-
tion of the SmCB1 zymogen was investigated using DS and hep-
arin derivatives of differing masses. Heparins with mass greater1792 Structure 22, 1786–1798, December 2, 2014 ª2014 Elsevier Ltdthan 3 kDa (corresponding to a decasaccharide) were effective,
whereas smaller octa- to disaccharides did not induce the
generation of SmCB1 activity (Figure 6C). Similarly, DSs were
effective over a broad mass range above 5 kDa (a 20-mer oligo-
saccharide); a 0.5 kDa disaccharide had no effect (Figure 6B).
Furthermore, the concentration dependence of the action of
SPs was demonstrated with DS of 9 to 20 kDa (used throughout
this study), which was highly effective above 10 mg/ml and inef-
fective at concentrations below 0.1 mg/ml (Figure S5).
In summary, only specific types of SPs accelerated the auto-
processing of the SmCB1 zymogen; a decasaccharide was the
minimal oligosaccharide length required.
The Alternative Processing Pathway Involving
Trans-Activation of SmCB1 by Asparaginyl
Endopeptidase Is Downregulated by SPs
We investigated the processing and activation of the SmCB1
zymogen catalyzed by proteolytic action of an asparaginylAll rights reserved
Figure 5. Autoprocessing of the SmCB1 Zymogen Containing a
Mutated Heparin-Binding Motif in the Propeptide
The zymogens of SmCB1 (CB) and its heparin-binding motif mutants, A57/A59
and N57/N59 (CBhA and CBhN, respectively) (75 nM) were incubated in the
presence and absence of DS (10 mg/ml) and analyzed at the indicated times.
The reaction was performed at pH 4.0 and 5.0, optimal for DS-independent
and DS-dependent processing, respectively. The reaction mixtures were
resolved by SDS-PAGE and visualized by protein staining. The position is
marked for the zymogen (pCB), intermediates (iCB), and mature enzyme
(mCB). The mCB form was not processed from pCBhA and pCBhN even at
longer incubation times.
Structure
Activation of Schistosoma mansoni Cathepsin B1endopeptidase fromS.mansoni (SmAE; Caffrey et al., 2000). The
recombinant SmAE efficiently converted the SmCB1 zymogen to
the mature form, which was associated with the generation of
SmCB1 activity (Figures 7A and 7C). This mature SmCB1 spe-
cies was formed in the absence of DS by the cleavage of the
propeptide at Asn69-Val70 (consistent with Sajid et al., 2003);
importantly, the same site we found in the mature enzyme ob-
tained by autocatalytic processing in the presence of DS (Fig-
ure S3). The highest trans-activation rate of the SmCB1 zymogen
by SmAE was in the pH range of 5.0 to 6.0 (Figure 7B), in which
SmAE is also active toward peptide substrates (Dalton et al.,
1995; Caffrey et al., 2000; Sajid et al., 2003).
In the next step, we tested the effect of DS on the trans-activa-
tion reaction catalyzed by SmAE.Wedemonstrated that the con-
version of the SmCB1 zymogen was substantially decreased in
the presence of DS, as shown by the processing pattern on
SDS-PAGE and by the yield of SmCB1 activity (the activation
rate was about one order of magnitude lower compared with
that in the absence of DS; Figures 7A and 7C). The depressive
effect of DS was not due to a direct impact on the proteolytic ac-
tivity of SmAE (measured with a peptide substrate; data not
shown). Note that the trans-activation experiments were not
interfered with by DS-mediated autoactivation, because they
were performed at pH 6, at which the autoactivation does not
proceed (Figure 3). Moreover, the active-site mutant of the
SmCB1 zymogen was used to analyze the processing pattern
(Figure 7A).
In conclusion, the SmCB1 zymogen was effectively matured
through proteolytic processing by SmAE at acidic pH up to pH
6.5; this process was downregulated by SPs.
DISCUSSION
SmCB1 is a critical protease in the digestion of hemoglobin as a
food source by the blood flukeS.mansoni and a promising target
for antischistosomal drugs. In this work, we describe the activa-
tionmechanism of the SmCB1 zymogen at themolecular and the
structural levels and provide evidence for a complex control of
the SmCB1 activation pathway by SPs.Structure 22, 1786–17In contrast to the zymogens of vertebrate cathepsins B (Mach
et al., 1994; Rozman et al., 1999; Caglic et al., 2007), the SmCB1
zymogen is unable to autocatalytically process into a fully mature
and active enzyme. This is in agreement with the previous find-
ings (Sajid et al., 2003). Autoprocessing truncates at the genera-
tion of an inactive intermediate iCBinact whereby the first half of
the propeptide is removed. We crystallographically character-
ized iCBinact and explain the lack of activity by showing that the
remaining intact part of the propeptide blocks the catalytic site
in the same pose as in the inactive SmCB1 zymogen. Impor-
tantly, this unproductive autoprocessing proceeds to completion
in the presence of SPs. Under these conditions, the zymogen is
converted into a fully active mature enzyme that lacks the entire
propeptide via an enzymatically active intermediate form iCBact.
The propeptide region that binds into the active site is cleaved in
the iCBact, thus opening its catalytic site for substrate entry.
SPs are reported to modulate papain-family cysteine pepti-
dases, including their ability to accelerate autoactivation as
found for several cathepsin L-type peptidases and human
cathepsin B (e.g., Ishidoh and Kominami, 1995; Quraishi et al.,
1999; Serveau et al., 2003; Vasiljeva et al., 2005; Caglic et al.,
2007). In the case of SmCB1, however, there is a strict require-
ment for SPs, which are the key factor to initiate and drive pro-
ductive autoactivation. For SmCB1, we hypothesized that a
consensus heparin-binding motif in its propeptide is the critical
binding site for SPs. The sequence motif is located in a noncon-
served a3p helix (Figure S1) and is absent in other structurally
investigated cathepsin B zymogens. Our recent sequence anal-
ysis revealed that this feature is specific for cathepsin B-type
peptidases of parasitic trematodes (flukes) that digest host pro-
teins (Horn et al., 2011). Our hypothesis was confirmed after we
constructed two zymogen mutants lacking the consensus motif:
both prevented SP-mediated autoprocessing to the mature
enzyme.
In order to gain structural insight into the SmCB1 activation
mechanism, we solved crystal structures for three processed
forms along the activation pathway, namely, the zymogen, inac-
tive intermediate iCBinact and mature enzyme. To date, similar
autoactivation intermediates have not been studied in detail for
cathepsins B (or other cysteine cathepsins) biochemically or at
the structural level. For human cathepsin B, temporary autopro-
cessing intermediates were detected, but attempts to interrupt
the autoactivation process and stabilize intermediates by muta-
tions at the propeptide/enzyme core junction were unsuccessful
(Quraishi et al., 1999; Pungercar et al., 2009). SmCB1, unable to
complete the autoactivation in the absence of SPs, offered an
opportunity to analyze the initial phase of the autoactivation
pathway involving the formation of intermediates. The iCBinact
is generated from the SmCB1 zymogen by processing at the
cleavage site Ser38-Leu39. This site is located on the a2p helix,
a solvent-exposed region that is far from the catalytic site to be
accessible to direct hydrolysis (Figure 1C). It may be expected
that the initial event in the autoprocessing is the destabilization
of the propeptide binding by a conformational change induced
by acidic pH, as has been proposed for other cysteine cathepsin
zymogens (Mach et al., 1994; McQueney et al., 1997; Me´nard
et al., 1998; Rozman et al., 1999). This would enable the
displacement of the propeptide from the active site and would
be supported by the occluding loop shifting from ‘‘open’’ to98, December 2, 2014 ª2014 Elsevier Ltd All rights reserved 1793
Figure 6. The Effect of Different SPs on the Autoactivation Processing of the SmCB1 Zymogen
The SmCB1 zymogen (75 nM) was incubated in the presence of different SPs (10 mg/ml) at pH 5.0, and the reaction mixtures were analyzed.
(A) The reaction mixtures incubated for the indicated times were resolved by SDS-PAGE and visualized by protein staining. The position is marked for the
zymogen (pCB), intermediates (iCB), and mature enzyme (mCB); co, unprocessed pCB control. The applied SPs: DS of 9 to 20 kDa (DS9–20), heparin of 17 to
19 kDa (Hep17–19), chondroitin-4-sulfate (C4S), chondroitin-6-sulfate (C6S), and dermatan-sulfate (DerS). (C4S, C6S and DerS were in the range of 20–60 kDa.)
(B and C) At the indicated time points, proteolytic activities generated in the reaction mixtures were measured in a kinetic assay with the substrate Z-Phe-Arg-
AMC at pH 6.0. Mean values ± SE are expressed in relative fluorescence units (RFU/s); the scale in (C) is zoomed to display slower heparin-mediated activation.
The molecular mass of the applied DS (B) and heparins (C) is indicated; the number of saccharide units in oligosaccharides is shown in parentheses.
Structure
Activation of Schistosoma mansoni Cathepsin B1‘‘closed’’ conformation as shown in the iCBinact structure (Fig-
ure 1B). The propeptide follows the active-site cleft in a reverse
direction to that of a substrate. Therefore, the Ser38-Leu39 hy-
drolysis could be accomplished by an intramolecular cleavage
after a major reorientation of the propeptide; nevertheless, an
interaction of two zymogenmolecules in the opposite orientation
would be more sterically favorable to insert productively the pro-
peptide in the neighboring active site. We found that the gener-
ation of iCBinact is concentration independent. This might reflect
the initial intramolecular conformational rearrangement of the
propeptide as a slow rate-limiting step, which is in line with the
slow-binding kinetics of the inhibition of cysteine cathepsins
with full-length propeptides (Fox et al., 1992; Quraishi et al.,
1999; Billington et al., 2000).
The mature SmCB1 was generated by SP-mediated autopro-
cessing via cleavage of Asn69-Val70 at the propeptide/enzyme
core junction. This solvent-exposed region is located in the vicin-
ity of the heparin-binding motif on the a3p helix of the propep-
tide. The a3p protruding above the enzyme core is stabilized
by a network of contacts formed between acidic and basic res-
idues (Figure 1C). This suggests that the interaction between the
heparin-binding motif and SPs will result in the destabilization ofSmCB1 processing forms were resolved by SDS-PAGE and visualized by immun
and mature enzyme (mCB).
(B) The SmCB1 zymogen and SmAE were incubated at various pH values for 2 hr
with the substrate Z-Phe-Arg-AMC at pH 6.0. Mean values ± SE are expressed i
(C) The SmCB1 zymogen and SmAEwere incubated at pH 6.0 in the presence or a
analyzed in a time course. The activity of the generated mature SmCB1 is not sig
1794 Structure 22, 1786–1798, December 2, 2014 ª2014 Elsevier Ltda3p. The subsequent conformational changes in the C-terminal
half of the propeptide will expose two regions of the propeptide
as a target for proteolysis: (1) the active site-binding region,
which is cleaved to release the active intermediate iCBact, and
(2) the propeptide/enzyme core junction, which is cleaved to pro-
duce the mature enzyme (Figures 1C and 4). We found that the
generation of the mature enzyme via iCBact is a concentration-
dependent process, indicating its bimolecular character. In the
first step, the mechanism of the formation of iCBact from the
zymogen might resemble that of iCBinact, in which, however,
SPs allow the removal of a larger part of the propeptide blocking
the catalytic site. In the second step, iCBact cleaves another
molecule of iCBact (or the zymogen) in complex with SP to give
rise to the mature enzyme, which enters the processing scheme
as demonstrated by its ability to effectively process the active-
site mutated zymogen in the presence of SP.
Our data imply that SPs convert the SmCB1 zymogen into a
better substrate for autocatalytic processing. This was demon-
strated by propeptide cleavage in the context of the zymogen
molecule. Moreover, we showed that the synthetic propeptide
scaffold became a better substrate for the mature enzyme,
which was largely attributed to the effect of the heparin-bindingFigure 7. Trans-Activation of the SmCB1
Zymogen by Asparaginyl Endopeptidase
The SmCB1 zymogen (75 nM) was incubated with
SmAE, an asparaginyl endopeptidase from
S. mansoni (5 nM), and the reaction mixture
analyzed.
(A) The reaction was performed in the presence or
absence of DS (10 mg/ml) at pH 6.0 for 6 hr. The
composition of the reaction mixtures is as indi-
cated: the active-site mutant of the SmCB1
zymogen (pCBas), SmAE (AE), and DS. The
ostaining. The position is marked for the zymogen (pCB), intermediates (iCB),
. The generated proteolytic activity of SmCB1 was measured in a kinetic assay
n relative fluorescence units (RFU/s).
bsence of DS (10 mg/ml), and the SmCB1 activities weremeasured as in (B) and
nificantly affected by DS under the assay conditions.
All rights reserved
Figure 8. The Activation Pathway of SmCB1
A mechanistic model for the proteolytic activation of the SmCB1 zymogen (pCB) via two alternative routes. The autocatalytic processing at acidic pH is un-
productive, leading to the inactive intermediate iCBinact with a partially removed propeptide that blocks the active site. The interaction of SPs with the heparin-
bindingmotif in the propeptide triggers productive autoactivation, which generates the active intermediate iCBact (having the accessible active site unhindered by
the residual propeptide), and finally the mature enzyme (mCB) with the fully removed propeptide. The trans-activation mediated by the proteolytic action of
S. mansoni asparaginyl endopeptidase (AE) leads to the same mature enzyme, but this processing step is suppressed by SPs. Therefore, SPs function as a
molecular switch between both activation routes.
Structure
Activation of Schistosoma mansoni Cathepsin B1motif (Figure 4). The minimal length of SPs required to induce the
autoactivation of the SmCB1 zymogen was a decasaccharide.
The critical size determined is similar to that observed for several
interactions between proteins and SPs (typically 6–12 saccha-
ride units; Gandhi and Mancera, 2008). The decasaccharide
length of 45 A˚ is sufficient to establish an interaction with the
C-terminal half of the SmCB1 propeptide (the zymogen size is
about 603 553 45 A˚). The fact that larger SPs exhibited a higher
induction effect on the SmCB1 autoactivation might be ex-
plained by a multivalent interaction with both the propeptide
and a positively charged region or regions on the enzyme core.
This is in line with our previous finding of large basic patches
on the surface of the mature SmCB1 (Horn et al., 2011).
The trans-activation of the SmCB1 zymogen by asparaginyl
endopeptidase leads to the mature enzyme through the cleav-
age of the same Asn69-Val70 site at the propeptide/mature
core junction that is processed during the SP-mediated autoac-
tivation. Surprisingly, this reaction was strongly suppressed by
SPs. We showed that SPs did not negatively influence the
SmAE activity toward peptide substrates, suggesting that SPs
might sterically hinder the SmAE-protein substrate interaction
by binding to SmCB1 and/or SmAE outside its active site.
In Figure 8, we summarize the results of this study and pro-
pose the following pathway for SmCB1 activation. There
are two alternative routes for the proteolytic activation of the
SmCB1 zymogen under a complex control of SPs. The autocat-
alytic activation requires SPs for productive processing, where-
as the trans-activation by endogenous SmAE is negatively
modulated by SPs. SPs thus function as a molecular switch be-
tween the two routes. Additional regulation might occur through
pH: the optimum pH ranges for autoactivation and trans-activa-
tion are about 4 to 5 and 5 to 6, respectively.Structure 22, 1786–17We believe that the discovered autoactivation route of SmCB1
mediated by SPs is biologically relevant. Indirect evidence can
be drawn from a recent study in which SmAE was knocked
down by RNAi in adult S. mansoni without any deleterious effect
on SmCB1 processing and activation (Krautz-Peterson and
Skelly, 2008). The required SPs are widespread in all animal tis-
sues, including endogenous GAGs in Schistosoma and exoge-
nous GAGs ingested with the human host’s blood, and their
physiological concentrations are comparable with those applied
in the present study (e.g., Bjo¨rnsson 1998; Nishio et al., 2011;
Mickum et al., 2014). The exact location(s) of SmCB1 processing
in the Schistosoma gut is unknown and may be in the gastroder-
mal syncytium and/or gut lumen; further research will be needed
to evaluate the functional relationship between the autoactiva-
tion and trans-activation routes.
In conclusion, we discover a dual activation pathway for
SmCB1, which is under complex control by SPs, and provide a
structural basis to explain the proteolytic mechanisms involved.
Our results give insights into the regulation of the SmCB1 drug
target and increase our understanding of GAG-protein inter-
actions that modulate the function of pathology-associated
cysteine cathepsins.EXPERIMENTAL PROCEDURES
Production and Purification of SmCB1
SmCB1 zymogen and its mutants were expressed in P. pastoris, including the
wild-type zymogen pCBWT, its nonglycosylated version pCB, and the pCB-
derived mutants of the heparin-binding motif (pCBhA and pCBhN) and the
active site (pCBas). Details on site-directed mutagenesis and expression are
provided in Supplemental Experimental Procedures. The mature SmCB1
(mCB) was derived from the pCB zymogen by trans-activation using SmAE,
as described previously (Horn et al., 2011). The SmCB1 intermediate (iCBinact)98, December 2, 2014 ª2014 Elsevier Ltd All rights reserved 1795
Table 1. X-Ray Data Collection and Refinement Statistics
Zymogen SmCB1 Intermediate SmCB1 Mature SmCB1
Data Collection Statistics
Wavelength (A˚) 0.914 0.979 0.97857
Temperature (K) 100 100 100
Space group P1 C2 P212121
a, b, c (A˚) 54.3, 83.2, 84.6 93.86, 50.99, 62.55 33.14, 79.17, 90.48
a, b, g () 76.9, 86.6, 71.1 90.0, 91.31, 90.0 90.0, 90.0, 90.0
Resolution (A˚) 50-1.95 (1.98-1.95) 50-1.9 (1.93-1.90) 50-1.30 (1.32-1.30)
No. of unique reflections 78,650 23,559 59,658
Redundancy 2.3 (1.9) 3.0 (2.7) 7.3 (5.7)
Completeness (%) 78.4 (42.1) 99.4 (98.7) 89.9 (49.3)
Rmerge
a 3.7 (29.6) 8.2 (35.0) 7.7 (43.8)
Average I/s (I) 25.9 (3.1) 18.2 (3.13) 33.7 (4.0)
Wilson B (A˚2) 25.2 20.2 13.5
Refinement Statistics
Resolution range (A˚) 38.4-1.95 (1.99-1.95) 26.6-1.9 (1.95-1.90) 19.79-1.3 (1.33-1.30)
No. of reflections in working set 71,614 (1,585) 22,109 (1,573) 50,812 (2,086)
No. of reflections in test set 3,756 (84) 1,201 (89) 2,711 (116)
R valueb (%) 19.93 (24.7) 16.31 (23.2) 13.74 (17.1)
Rfree value
c (%) 25.24 (28.5) 21.64 (27.1) 17.67 (21.5)
No. of atoms in AU all/protein/solvent 10,371/9,828/519 2,619/2,278/340/1Na ion 2,531/2,099/437
Average ADP for all/main-chain/side-chain and
solvent atoms (A˚2)
25.29/24.44/26.43 23.2/21.9/32.1 11.5/7.82/14.09
Rmsd bond length (A˚) 0.012 0.013 0.013
Rmsd bond angle () 1.303 1.487 1.437
Ramachandran plot statistics
Residues in favored regions (%) 96.1 96.6 96.3
Residues in allowed regions (%) 99.9 100 100
PDB accession number 4I04 4I05 4I07
Numbers in parentheses refer to the highest-resolution shell. AU, asymmetric unit; ADP, atomic displacement parameter, formally B factor.
aRmerge = ShklSiIi(hkl) hI(hkl)ij/ShklSiIi(hkl), where Ii(hkl) is an individual intensity of the ith observation of reflection hkl and hI(hkl)i is the average intensity
of reflection hkl with summation over all data.
bR value = jjFoj  jFcjj/jFoj, where Fo and Fc are the observed and calculated structure factors, respectively.
cRfree is equivalent to the R value but is calculated for 5% of the reflections chosen at random and omitted from the refinement process.
Structure
Activation of Schistosoma mansoni Cathepsin B1was obtained by the autoprocessing of pCB at pH 4.0 (see Supplemental
Experimental Procedures). Both processed forms and the active-site mutated
zymogen pCBas were purified using aMono SHR 5/5 column under conditions
previously described (Horn et al., 2011).
Crystallization and Structure Determination
Crystals of mCB, iCBinact, and pCBas were obtained by vapor diffusion in
hanging drop as described in Supplemental Experimental Procedures. Diffrac-
tion data were collected using synchrotron radiation, and the structures were
determined by molecular replacement using the structure of mature SmCB1 in
complex with CA-074 (Protein Data Bank [PDB] accession number 3QSD) as
the search model (for details, see Supplemental Experimental Procedures).
Data collection and refinement statistics are given in Table 1. Graphical repre-
sentations were prepared with PyMOL Molecular Graphics System (Schro¨-
dinger). The part of the occluding loop of the pCBas crystal structure without
adequate electron density was modeled as described in Supplemental Exper-
imental Procedures.
Autocatalytic Processing of SmCB1
SmCB1 zymogen (various mutants, 75 nM final concentration) was
autoprocessed by incubation at 37C in 1.5 ml of appropriate activation1796 Structure 22, 1786–1798, December 2, 2014 ª2014 Elsevier Ltdbuffer (see below) in the absence and presence of DS of 9 to 20 kDa
(used throughout this study, unless specified otherwise) at a final con-
centration of 10 mg/ml. The following buffers were used: 0.1 M sodium
acetate (pH 4.0—5.5) and 0.1 M sodium phosphate (pH 6.0–8.0). All acti-
vation buffers contained 2.5 mM dithiothreitol (DTT), 1 mM EDTA, and
0.1% polyethylene glycol (PEG) 6000. Aliquots of 5 ml were taken from
the reaction mixture at different time intervals, and activity of SmCB1
was measured in a kinetic assay with the substrate Z-Phe-Arg-AMC.
Simultaneously, 300 ml aliquots of the reaction mixture were withdrawn,
processing was stopped by adding E-64 to 10 mM concentration, and
acetone-precipitated proteins were analyzed by SDS-PAGE. This assay
for the autocatalytic processing of SmCB1 was modified as described in
Supplemental Experimental Procedures to analyze the effect of DS con-
centration, SP types, E-64, glycerol, pCB concentration, and pCBas pro-
cessing by mature SmCB1.
Trans-Activation of SmCB1 by SmAE
The pCB zymogen (75 nM) was trans-activated by incubation with SmAE
(5 nM) at 37C in the presence or absence of DS (10 mg/ml) in 100 ml of the
following buffers: 0.1 M sodium acetate (pH 4.0–5.5) and 0.1 M sodium phos-
phate (pH 6.0–8.0). All buffers contained 2.5 mM DTT, 1 mM EDTA, and 0.1%All rights reserved
Structure
Activation of Schistosoma mansoni Cathepsin B1PEG 6000. Aliquots of 5 ml were taken from the reaction mixture at different
time intervals, and activity of SmCB1 was measured in a kinetic assay with
the substrate Z-Phe-Arg-AMC. The pCBas zymogen (75 nM) was processed
by SmAE (5 nM) at 37C for 6 hr in 300 ml in the same buffer (pH 6.0) in the pres-
ence or absence of DS (10 mg/ml). The reaction mixtures were acetone precip-
itated, resolved by SDS-PAGE, and analyzed by immunoblotting using SmCB1
specific antibodies.
Proteolytic Activity Measurement
Enzymatic activity of SmCB1 was measured in a kinetic continuous assay us-
ing the fluorogenic substrate Z-Phe-Arg-AMC. Assay was performed in a 96-
well microplate format in a total assay volume of 200 ml at 37C. The assay
mixture contained an aliquot of the SmCB1 processing reaction (5 ml) and
25 mM Z-Phe-Arg-AMC in 0.1 M sodium phosphate (pH 6.0), 2.5 mM DTT,
0.1%PEG 6000, and 1mMEDTA. The kinetics of product release were contin-
uously monitored in an Infinite M1000 microplate reader (Tecan) at excitation
and emission wavelengths of 360 and 465 nm, respectively. All experiments
were performed in duplicate. SmAE activity measurement and the active-
site titration method (Horn et al., 2009) are described in Supplemental Exper-
imental Procedures.Imaging and Analytical Methods
SDS-PAGE was performed under reducing conditions on 15% Laemmli
gels. Aliquots of reaction mixtures were protein precipitated with acetone,
resolved by SDS-PAGE, and the gel was visualized by protein staining with
Coomassie Brilliant Blue or silver nitrate. Processing sites were identified
by N-terminal protein sequencing after electroblotting of SDS-PAGE
gels. Active-site labeling of SmCB1 with Green-DCG-04 is described in
Supplemental Experimental Procedures. Propeptide fragments were syn-
thesized as described previously (Doleckova´-Maresova´ et al., 2005; Horn
et al., 2011), fragmented with mature SmCB1 and SmAE, and analyzed
by mass spectrometry as described in Supplemental Experimental
Procedures.ACCESSION NUMBERS
The PDB accession numbers for the zymogen, intermediate, andmature forms
of SmCB1 are 4I04, 4I05, and 4I07, respectively.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
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